Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors

Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, Weide B, Gutzmer R, Becker JC, Kiecker F, Daehling A, Funkner F, Heidenreich R, Kays SK, Klinkhardt U, Scheel B, Schoenborn-Kellenberger O, Seibel T, Stosnach C, Strack T, Gnad-Vogt U (2019)


Publication Type: Conference contribution

Publication year: 2019

Journal

Publisher: AMER ASSOC CANCER RESEARCH

City/Town: PHILADELPHIA

Conference Proceedings Title: CANCER RESEARCH

Event location: Atlanta, GA US

DOI: 10.1158/1538-7445.AM2019-LB-021

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Eigentler, T., Krauss, J., Schreiber, J., Weishaupt, C., Terheyden, P., Heinzerling, L.,... Gnad-Vogt, U. (2019). Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors. In CANCER RESEARCH. Atlanta, GA, US: PHILADELPHIA: AMER ASSOC CANCER RESEARCH.

MLA:

Eigentler, Thomas, et al. "Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors." Proceedings of the AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, Atlanta, GA PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2019.

BibTeX: Download